Please assess the completion status of the following clinical trial:

Trial Title: Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age below 18 years~* Neonatal diabetes secondary to documented mutation in one of the 2 sub units of potassium channels~* Patients already treated by glibenclamide pills~* Signed consent~Exclusion Criteria:~* Families unable to fill in the questionnaries~* Patients unable to answer to the visual hedonic squale~* Patients unable to take the oral solution~* Known allergy to sulfonylureas or to other antidiabetic or antibiotic sulfamides~* Insulin therapy associated to glibenclamide~* Miconazole therapy~* Porphyria~* Breast feeding~* Severe renal failure (creatinine clearance below 30 ml/mn)~* Liver failure (prothombine time below 70)~* Not affiliated to the health care system

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Patients with neonatal diabetes (Type: EXPERIMENTAL): Patients with neonatal diabetes

Based on this trial design, predict the completion outcome and termination type (if applicable).